Dr. Reddy's Laboratories Limited
Explore Dr. Reddy's Laboratories Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
RDY — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zoetis Inc. | $79.44 | 12.31 | $32.53 B | 1.64% | 27.18% | 62.41% | $171.52 / $72.38 | $7.84 |
| 2. | United Therapeutics Corporation | $549.87 | 18.12 | $23.32 B | — | 20.73% | 19.24% | $609.35 / $272.12 | $162.6 |
| 3. | Viatris Inc. | $15.88 | — | $18.12 B | 3.09% | 0.84% | -1.97% | $17.53 / $8.44 | $12.78 |
| 4. | Neurocrine Biosciences, Inc. | $163.88 | 24.8 | $16.58 B | — | 16.37% | 21.64% | $169.57 / $122.14 | $32.5 |
| 5. | Elanco Animal Health Incorporated | $23.63 | — | $11.8 B | — | 2.14% | -3.64% | $27.72 / $13.16 | $13.17 |
| 6. | Alkermes plc | $42.8 | 47.15 | $7.2 B | — | 13.07% | 8.82% | $44.57 / $25.17 | $10.99 |
| 7. | Lantheus Holdings, Inc. | $100.98 | 23.94 | $6.68 B | — | 16.66% | 24.33% | $104 / $47.25 | $16.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 920.04 M | 928.29 M | 900.89 M | 896.76 M | 881.22 M | — |
| Operating Profit | 151.08 M | 188.37 M | 177.56 M | 182.89 M | 197.23 M | — |
| Net Profit | 127.55 M | 151.52 M | 149.47 M | 168.03 M | 149 M | — |
| EPS in Rs | 0.15 | 0.18 | 0.18 | — | 0.18 | 0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.43 B | 2.94 B | 2.59 B | 2.26 B |
| Operating Profit | 759.22 M | 688.52 M | 622.59 M | 378.68 M |
| Net Profit | 596.13 M | 587.06 M | 475.13 M | 248.47 M |
| EPS in Rs | 0.72 | 0.71 | 0.57 | 0.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.2 B | 4.09 B | 3.39 B | 3.09 B |
| Total Liabilities | 1.64 B | 1.13 B | 957.94 M | 1.08 B |
| Equity | 3.51 B | 2.96 B | 2.44 B | 2.01 B |
| Current Assets | 2.64 B | 2.62 B | 2.15 B | 1.92 B |
| Current Liabilities | 1.37 B | 1.01 B | 905.04 M | 991.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 489.48 M | 478.99 M | 620.7 M | 296.33 M |
| Investing CF | -612.29 M | -424.69 M | -436.18 M | -278.19 M |
| Financing CF | 199.37 M | -39.67 M | -283.19 M | -25.53 M |
| Free CF | 126.83 M | 189.75 M | 421.8 M | 95.51 M |
| Capex | -362.65 M | -289.24 M | -198.9 M | -200.83 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 16.61% | 13.54% | 14.69% | — |
| Earnings Growth % | 1.54% | 23.56% | 91.22% | — |
| Profit Margin % | 17.37% | 19.95% | 18.33% | 10.99% |
| Operating Margin % | 22.12% | 23.39% | 24.02% | 16.75% |
| Gross Margin % | 58.5% | 58.61% | 56.67% | 53.1% |
| EBITDA Margin % | 29.7% | 31.67% | 30.27% | 21.03% |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-07-25 | $0.091 |
| 2024-07-30 | $0.0958 |
| 2023-07-28 | $0.0976 |
| 2023-07-07 | $0.0976 |
| 2022-08-01 | $0.0756 |
Stock Splits
| Date | Split |
|---|---|
| 2024-11-05 | 1:5 |
| 2006-09-07 | 1:2 |
Frequently Asked Questions — Dr. Reddy's Laboratories Limited
Will Dr. Reddy's Laboratories Limited stock hit $16 in 2026?
Dr. Reddy's Laboratories Limited (RDY) is currently trading at $13.24, with a 52-week range of $12.06 to $14.49. Reaching the $16 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Wall Street analysts currently have a consensus price target of $14.23 for Dr. Reddy's Laboratories Limited, with a Hold rating, and the most bullish analysts see the stock reaching as high as $16.41. Whether Dr. Reddy's Laboratories Limited can reach $16 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the RDY Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Dr. Reddy's Laboratories Limited stock worth buying at $13.24?
Whether Dr. Reddy's Laboratories Limited (RDY) is worth buying at $13.24 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Dr. Reddy's Laboratories Limited trades at a Price-to-Earnings (P/E) ratio of 25.2x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.
Profitability & efficiency: Its Return on Equity (ROE) stands at 4.2%.
Financial health: The Debt-to-Equity ratio of 18.03 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.
Analyst view: The Wall Street consensus recommendation for RDY is currently Hold, with a mean price target of $14.23 based on 5 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Dr. Reddy's Laboratories Limited (RDY) in 2026?
As of 2026, Wall Street analysts have set a consensus (mean) price target of $14.23 for Dr. Reddy's Laboratories Limited (RDY), aggregated from 5 analyst ratings. The overall analyst recommendation is Hold.
The price target range spans from $11.39 on the bearish end to $16.41 on the most optimistic projection, with a median target of $13.83. This wide range reflects differing views on Dr. Reddy's Laboratories Limited's growth prospects, competitive positioning, and macroeconomic sensitivity.
It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the RDY analysis page on StockSifting.
Is Dr. Reddy's Laboratories Limited overvalued at a P/E ratio of 25.2x?
Dr. Reddy's Laboratories Limited (RDY) currently has a Price-to-Earnings (P/E) ratio of 25.2x, meaning investors are paying $25.2 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:
Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 25.2x P/E falls within a moderate range, reflecting reasonable market confidence in Dr. Reddy's Laboratories Limited's earnings outlook.
Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation.
Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of RDY's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.
How much can you earn by reinvesting Dr. Reddy's Laboratories Limited dividends?
Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of Dr. Reddy's Laboratories Limited (RDY). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.
Dr. Reddy's Laboratories Limited currently offers a dividend yield of approximately 1.00%. While this may seem modest in isolation, the real power of DRIP emerges over long holding periods. An investor who reinvested dividends consistently over 10–20 years would accumulate significantly more shares than one who took dividends as cash — and those extra shares continue generating their own dividend income.
The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether Dr. Reddy's Laboratories Limited grows or cuts its dividend over time. Market price appreciation of RDY also plays a significant role — rising share prices increase the value of your accumulated shares.
Use the RDY DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.